Table 3.
Secondary analyses: comparison of PMLR versus maximal medical therapy for all outcomes using data from the DIRECT trial high-dose group
| Variable | Pooled standardized mean difference | Pooled odds ratio | 95% CI for difference | P-value |
|---|---|---|---|---|
| CCS class | _ | 1.95 | [0.90, 4.23] | 0.09 |
| Self-reported HRQL | ||||
| SAQ – AF | 0.18 | _ | [–0.20, 0.57] | 0.35 |
| SAQ – AS | 0.01 | _ | [–0.23, 0.24] | 0.95 |
| SAQ – DP | 0.10 | _ | [–0.25,0.45] | 0.57 |
| SAQ – PL | 0.01 | _ | [–0.23, 0.24] | 0.95 |
| SAQ – TS | −0.005 | _ | [–0.30, 0.20] | 0.72 |
| Exercise duration | 0.17 | _ | [–0.18, 0.53] | 0.97 |
| All-cause mortality | _ | 1.34 | [0.44, 4.03] | 0.61 |
Abbreviations: AF, angina frequency; AS, angina stability; CCS, Canadian Cardiovascular Society; DP, disease perception; HRQL, health-related quality of life; PL, physical limitation; SAQ, Seattle Angina Questionnaire; TS, treatment satisfaction.